1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Genexine Advances DNA Vaccine With Mid-Stage Cervical Cancer Success

In Regimen With Keytruda

 
• By Ayisha Sharma

The Korean firm’s DNA vaccine has shown promise in a Phase II cervical cancer trial in combination with Merck’s Keytruda, prompting the firm to tout potential in the difficult PD-1 negative group.  

The doctor holds an ampoule with a vaccine. Hand in medical glove. Concept of danger or need for vaccination.
DNA Vaccines Work Similarly To The Better Known mRNA Vaccines • Source: Shutterstock

Genexine Inc.’s first-in-class DNA therapeutic vaccine candidate for HPV-related cancers, GX-188E, has impressed in a challenging cohort of cervical cancer patients in combination with Merck & Co., Inc.’s Keytruda (pembrolizumab) in a mid-stage study.

The Phase II trial enrolled 60 people with advanced HPV 16 – or 18- positive cervical cancer who had progressed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

More from Therapy Areas